Ivan P. Gergel Sells 8,389 Shares of Nektar Therapeutics (NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 8,389 shares of the business’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $21.04, for a total transaction of $176,504.56. Following the sale, the senior vice president now directly owns 51,961 shares in the company, valued at approximately $1,093,259.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nektar Therapeutics (NASDAQ NKTR) opened at 19.64 on Wednesday. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The stock’s market capitalization is $3.05 billion. The company has a 50-day moving average of $20.53 and a 200 day moving average of $18.09.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.03. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The firm had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. During the same period in the prior year, the firm posted ($0.36) earnings per share. Nektar Therapeutics’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Nektar Therapeutics will post ($1.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ivan P. Gergel Sells 8,389 Shares of Nektar Therapeutics (NKTR) Stock” was first published by BBNS and is the sole property of of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/ivan-p-gergel-sells-8389-shares-of-nektar-therapeutics-nktr-stock-updated-updated-updated/1199174.html.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after buying an additional 20,024,448 shares in the last quarter. Camber Capital Management LLC boosted its position in Nektar Therapeutics by 87.5% in the fourth quarter. Camber Capital Management LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock worth $73,620,000 after buying an additional 2,800,000 shares in the last quarter. Norges Bank purchased a new position in Nektar Therapeutics during the fourth quarter worth approximately $31,574,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of Nektar Therapeutics during the first quarter worth $23,580,000. Finally, Marshall Wace North America L.P. bought a new stake in shares of Nektar Therapeutics during the first quarter worth $23,580,000. 94.09% of the stock is owned by hedge funds and other institutional investors.

NKTR has been the topic of a number of analyst reports. Jefferies Group LLC lowered their target price on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Aegis reissued a “buy” rating and set a $27.00 target price on shares of Nektar Therapeutics in a report on Wednesday, May 10th. Roth Capital set a $31.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Thursday, May 11th. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $29.00 price target on shares of Nektar Therapeutics in a research report on Tuesday, April 11th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $26.56.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.